| Ashley Weaver, RPH | |
|
203 N Main St, Fountain Inn, SC 29644-1907 | |
| (864) 862-4414 | |
| Not Available |
| Full Name | Ashley Weaver |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 203 N Main St, Fountain Inn, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831552736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 36485 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Weaver, RPH 203 N Main St, Fountain Inn, SC 29644-1907 Ph: () - | Ashley Weaver, RPH 203 N Main St, Fountain Inn, SC 29644-1907 Ph: (864) 862-4414 |
News Archive
The Pennsylvania Human Relations Commission issued an order today dismissing a racial discrimination complaint filed by Maria Thompson-White of Merchantville, New Jersey, against her former employer, Lycoming House, a drug addiction treatment center in Philadelphia.
The problem of child sexual abuse in sub-Saharan Africa remains "stubbornly resistant to change" in part because of the traditionally low status of girls, a "lingering view" that sexual abuse should be dealt with privately and justice systems that "constitute obstacle courses" for women, some child advocates have said, the New York Times reports.
The US Health and Human Services administration announced $320 million in new grants under the Affordable Care Act (ACA) to strengthen the healthcare workforce in America. Florida alone will receive more than $11 million in grant funding.
A protein produced by the central nervous system's support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 7 days ago
Natalie Sult, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 104 Quercus Run, Fountain Inn, SC 29644 Phone: 864-569-5335 | |
Deborah Causey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 203 N Main St, Fountain Inn, SC 29644 Phone: 864-862-4414 Fax: 864-862-0592 | |
Mr. Douglas Hansford Netterville, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 248 Ivy Woods Ct, Fountain Inn, SC 29644 Phone: 901-334-8542 | |
Ashish B Patel, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1103 N Main St Ste E, Fountain Inn, SC 29644 Phone: 864-210-1811 Fax: 864-210-1810 | |
Allison Landreth, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 308 Chinchilla Dr, Fountain Inn, SC 29644 Phone: 864-404-9532 | |
Mrs. Leah M Mauritz, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 203 N. Main St., Fountain Inn, SC 29644 Phone: 864-862-4414 |